Total Daily (Image 1)
Levetiracetam Solution
Product Images NDC 0472-0235
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0472-0235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Levetiracetam-figure-5 (Image 10)
This appears to be a table or chart showing data for two groups of patients, one treated with a placebo and the other with a medication called Levetiacetam. The first entry indicates the percentage of patients that the data applies to. The next line may represent the number of patients involved in the study. Not enough context is available to provide additional information.*
Image (Image 11)
This text is a set of instructions and guidelines for dispensing and storing an oral solution medication called Levetiracetam. The dosage recommendations are not given in the text and must be accessed through additional product information. The medication should be stored in a light-resistant container with a child-resistant closure at room temperature, with excursions permitted between 10-30°C. Pharmacists are also instructed to provide a medication guide to each patient receiving this medication.*
0.85 Image (Image 2)
1.73 Image (Image 3)
This text appears to be providing certain numerical values related to the clearance rate (in mL/min) of a subject measured in terms of body surface area (BSA) in square meters. The value of Cler (mL/min/1.73 m?) seems to be missing, and the value given for BSA subject is multiplied by 1.73. However, it is not clear what exactly this information is intended for or what kind of subject is being referred to.*
0ccff95d-figure-04 (Image 4)
Figure1leve (Image 5)
Figure2leve (Image 6)
This appears to be a table of data related to patients and their dosage of a medication called Levetiracetam. The table includes percentages of patients at various dosage levels, including a placebo group. However, the specifics of the data are unclear due to the incomplete nature of the text provided.*
Figure3leve (Image 7)
This appears to be a table showing patient data for a clinical trial. The first column contains percentages. There is no clear indication of what the percentages denote. The second column shows the number 144%, and the third column shows the number 394%. The next two rows are blank. The next row shows that there were 104 patients in the placebo group. The final row shows the medication "Levetiracetam" and a dosage of 3000 mg/day.*
Figure 4 (Image 8)
This appears to be a chart or table showing the percentage of patients in a study who were either given a placebo or the medication Levetiracetam. The percentages given for each group are 196% and 44.6%. However, without any context or additional information it is unclear what these percentages represent or what the study was evaluating.*
Fig5 (Image 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
